ABT
Income statement / Annual
Last year (2024), Abbott Laboratories's total revenue was $41.95 B,
an increase of 4.59% from the previous year.
In 2024, Abbott Laboratories's net income was $13.40 B.
See Abbott Laboratories,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$41.95 B |
$40.11 B |
$43.65 B |
$43.08 B |
$34.61 B |
$31.90 B |
$30.58 B |
$27.39 B |
$20.85 B |
$20.41 B |
| Cost of Revenue |
$18.71 B
|
$17.98 B
|
$19.14 B
|
$18.54 B
|
$15.00 B
|
$13.23 B
|
$12.71 B
|
$12.34 B
|
$9.02 B
|
$8.75 B
|
| Gross Profit |
$23.24 B
|
$22.13 B
|
$24.51 B
|
$24.54 B
|
$19.61 B
|
$18.67 B
|
$17.87 B
|
$15.05 B
|
$11.83 B
|
$11.66 B
|
| Gross Profit Ratio |
0.55
|
0.55
|
0.56
|
0.57
|
0.57
|
0.59
|
0.58
|
0.55
|
0.57
|
0.57
|
| Research and Development Expenses |
$2.84 B
|
$2.74 B
|
$2.89 B
|
$2.74 B
|
$2.42 B
|
$2.44 B
|
$2.30 B
|
$2.24 B
|
$1.42 B
|
$1.41 B
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$9.74 B
|
$9.12 B
|
$6.67 B
|
$6.79 B
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$11.70 B
|
$10.95 B
|
$11.25 B
|
$11.32 B
|
$9.70 B
|
$9.77 B
|
$9.74 B
|
$9.12 B
|
$6.67 B
|
$6.79 B
|
| Other Expenses |
$1.88 B
|
$1.97 B
|
$2.01 B
|
$2.05 B
|
$2.13 B
|
$1.94 B
|
$139.00 M
|
$1.25 B
|
-$945.00 M
|
$281.00 M
|
| Operating Expenses |
$16.42 B
|
$15.66 B
|
$16.15 B
|
$16.11 B
|
$14.25 B
|
$14.14 B
|
$14.22 B
|
$13.33 B
|
$8.64 B
|
$8.79 B
|
| Cost And Expenses |
$35.13 B
|
$33.63 B
|
$35.29 B
|
$34.65 B
|
$29.25 B
|
$27.37 B
|
$26.93 B
|
$25.66 B
|
$17.67 B
|
$17.54 B
|
| Interest Income |
$344.00 M
|
$385.00 M
|
$183.00 M
|
$43.00 M
|
$46.00 M
|
$94.00 M
|
$105.00 M
|
$124.00 M
|
$99.00 M
|
$105.00 M
|
| Interest Expense |
$559.00 M
|
$637.00 M
|
$375.00 M
|
$490.00 M
|
$500.00 M
|
$576.00 M
|
$721.00 M
|
$780.00 M
|
$332.00 M
|
$58.00 M
|
| Depreciation & Amortization |
$3.22 B
|
$3.24 B
|
$3.27 B
|
$3.54 B
|
$3.33 B
|
$3.01 B
|
$3.28 B
|
$3.02 B
|
$1.35 B
|
$601.00 M
|
| EBITDA |
$10.83 B |
$10.61 B |
$12.38 B |
$12.74 B |
$8.79 B |
$7.77 B |
$7.12 B |
$6.13 B |
$3.07 B |
$4.83 B |
| EBITDA Ratio |
0.26
|
0.26
|
0.25
|
0.25
|
0.22
|
0.21
|
0.2
|
0.18
|
0.13
|
0.18
|
| Operating Income Ratio |
0.16
|
0.16
|
0.19
|
0.2
|
0.15
|
0.14
|
0.12
|
0.06
|
0.15
|
0.14
|
| Total Other Income/Expenses Net |
$188.00 M
|
$186.00 M
|
-$56.00 M
|
-$214.00 M
|
-$389.00 M
|
-$455.00 M
|
-$777.00 M
|
$667.00 M
|
-$1.61 B
|
$316.00 M
|
| Income Before Tax |
$7.01 B
|
$6.66 B
|
$8.31 B
|
$8.21 B
|
$4.97 B
|
$4.08 B
|
$2.87 B
|
$2.23 B
|
$1.41 B
|
$3.18 B
|
| Income Before Tax Ratio |
0.17
|
0.17
|
0.19
|
0.19
|
0.14
|
0.13
|
0.09
|
0.08
|
0.07
|
0.16
|
| Income Tax Expense |
-$6.39 B
|
$941.00 M
|
$1.37 B
|
$1.14 B
|
$497.00 M
|
$390.00 M
|
$539.00 M
|
$1.88 B
|
$350.00 M
|
$577.00 M
|
| Net Income |
$13.40 B
|
$5.72 B
|
$6.93 B
|
$7.07 B
|
$4.50 B
|
$3.69 B
|
$2.37 B
|
$477.00 M
|
$1.40 B
|
$4.42 B
|
| Net Income Ratio |
0.32
|
0.14
|
0.16
|
0.16
|
0.13
|
0.12
|
0.08
|
0.02
|
0.07
|
0.22
|
| EPS |
7.74 |
3.3 |
3.94 |
3.97 |
2.52 |
2.07 |
1.35 |
0.27 |
0.95 |
3 |
| EPS Diluted |
7.67 |
3.27 |
3.91 |
3.94 |
2.5 |
2.06 |
1.34 |
0.27 |
0.94 |
2.94 |
| Weighted Average Shares Out |
$1.73 B
|
$1.73 B
|
$1.75 B
|
$1.78 B
|
$1.77 B
|
$1.77 B
|
$1.76 B
|
$1.74 B
|
$1.47 B
|
$1.47 B
|
| Weighted Average Shares Out Diluted |
$1.75 B
|
$1.75 B
|
$1.76 B
|
$1.79 B
|
$1.79 B
|
$1.78 B
|
$1.77 B
|
$1.75 B
|
$1.48 B
|
$1.51 B
|
| Link |
|
|
|
|
|
|
|
|
|
|
